Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - vTv Therapeutics Inc. | vtvt-ex322_6.htm |
| EX-32.1 - EX-32.1 - vTv Therapeutics Inc. | vtvt-ex321_11.htm |
| EX-31.2 - EX-31.2 - vTv Therapeutics Inc. | vtvt-ex312_7.htm |
| EX-31.1 - EX-31.1 - vTv Therapeutics Inc. | vtvt-ex311_8.htm |
| EX-21.1 - EX-21.1 - vTv Therapeutics Inc. | vtvt-ex211_12.htm |
| EX-10.17 - EX-10.17 - vTv Therapeutics Inc. | vtvt-ex1017_589.htm |
| EX-4.1 - EX-4.1 - vTv Therapeutics Inc. | vtvt-ex41_480.htm |
| 10-K - VTVT-10K-12312016 - vTv Therapeutics Inc. | vtvt-10k_20161231.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Registration Statement No. 333-206335 on Form S-8 of our report dated February 24, 2017, with respect to the consolidated financial statements of vTv Therapeutics Inc. included in this Annual Report on Form 10-K of vTv Therapeutics Inc. for the year ended December 31, 2016.
/s/ Ernst & Young LLP
Raleigh, North Carolina
February 24, 2017